Sublingual Tablet Articles & Analysis: Older

1 news found

BioLingus to Develop a Sublingual Vaccine for COVID in Cooperation With the Korean CHA Vaccine Institute and PanGen Biotech

The granted R&D project is 'Development of sublingual COVID-19 subunit vaccine,' in which CHA Vaccine Institute, PanGen Biotech, and BioLingus will develop a sublingual tablet or drop type of recombinant subunit COVID-19 vaccine. Sublingual vaccines as a tablet type are dissolved under the tongue and absorbed ...

Sep. 7, 2022

ByBioLingus AG

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you